{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T00:55:03Z","timestamp":1787532903149,"version":"build-2736575974"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T00:00:00Z","timestamp":1777507200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T00:00:00Z","timestamp":1777507200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100005614","name":"Biogen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005614","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1007\/s12325-026-03608-1","type":"journal-article","created":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T09:17:51Z","timestamp":1777540671000},"page":"3031-3042","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Comparative Effectiveness of Diroximel Fumarate vs. Dimethyl Fumarate in Persons with Multiple Sclerosis: A US Claims Analysis of Relapse Outcomes"],"prefix":"10.1007","volume":"43","author":[{"given":"Daniel","family":"Bandari","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5359-6686","authenticated-orcid":false,"given":"Devon","family":"Conway","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-5300-4547","authenticated-orcid":false,"given":"Liang","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-6004-3690","authenticated-orcid":false,"given":"Nicholas","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-5828-9458","authenticated-orcid":false,"given":"Minxing","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-9357-8993","authenticated-orcid":false,"given":"Anne","family":"Littlewood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6675-660X","authenticated-orcid":false,"given":"Mike","family":"Roy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8729-0869","authenticated-orcid":false,"given":"Sam","family":"Ulin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chencan","family":"Zou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-5117-9871","authenticated-orcid":false,"given":"Babak","family":"Amerian-Williams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas","family":"Belviso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2352-9113","authenticated-orcid":false,"given":"James B.","family":"Lewin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2526-5542","authenticated-orcid":false,"given":"Jason P.","family":"Mendoza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0605-9559","authenticated-orcid":false,"given":"Mirla","family":"Avila","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,30]]},"reference":[{"issue":"6","key":"3608_CR1","doi-asserted-by":"publisher","first-page":"s53","DOI":"10.7861\/clinmedicine.16-6-s53","volume":"16","author":"A Doshi","year":"2016","unstructured":"Doshi A, Chataway J. Multiple sclerosis, a treatable disease. Clin Med. 2016;16(6):s53\u20139.","journal-title":"Clin Med"},{"issue":"1","key":"3608_CR2","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1007\/s40120-017-0064-x","volume":"6","author":"A Boster","year":"2017","unstructured":"Boster A, Nicholas J, Wu N, et al. Comparative effectiveness research of disease-modifying therapies for the management of multiple sclerosis: analysis of a large health insurance claims database. Neurol Ther. 2017;6(1):91\u2013102.","journal-title":"Neurol Ther"},{"key":"3608_CR3","unstructured":"National Multiple Sclerosis Society. Disease-modifying therapies. https:\/\/www.nationalmssociety.org. Accessed 23 Jan 2026."},{"issue":"4","key":"3608_CR4","doi-asserted-by":"publisher","first-page":"1810","DOI":"10.1007\/s12325-022-02068-7","volume":"39","author":"S Wray","year":"2022","unstructured":"Wray S, Then Bergh F, Wundes A, et al. Efficacy and safety outcomes with diroximel fumarate after switching from prior therapies or continuing on DRF: results from the phase\u00a03 EVOLVE-MS-1 study. Adv Ther. 2022;39(4):1810\u201331.","journal-title":"Adv Ther"},{"issue":"1","key":"3608_CR5","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1007\/s40120-024-00680-z","volume":"14","author":"KS Pandey","year":"2025","unstructured":"Pandey KS, Giles K, Balashov K, et al. Long-term safety and effectiveness of dimethyl fumarate in patients with multiple sclerosis treated in routine medical practice: final analysis of the ESTEEM study. Neurol Ther. 2025;14(1):243\u201360.","journal-title":"Neurol Ther"},{"issue":"12","key":"3608_CR6","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1056\/NEJMoa1114287","volume":"367","author":"R Gold","year":"2012","unstructured":"Gold R, Kappos L, Arnold DL, et al. Placebo-controlled phase\u00a03 study of oral BG-12 for relapsing multiple sclerosis. N Engl J Med. 2012;367(12):1098\u2013107.","journal-title":"N Engl J Med"},{"issue":"5","key":"3608_CR7","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1177\/13524585211037909","volume":"28","author":"R Gold","year":"2022","unstructured":"Gold R, Arnold DL, Bar-Or A, et al. Long-term safety and efficacy of dimethyl fumarate for up to 13\u00a0years in patients with relapsing-remitting multiple sclerosis: final ENDORSE study results. Mult Scler J. 2022;28(5):801\u201316.","journal-title":"Mult Scler J"},{"issue":"1","key":"3608_CR8","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1007\/s40120-022-00413-0","volume":"12","author":"B Lager","year":"2023","unstructured":"Lager B, Liseno J, Bo\u017ein I, et al. Real-world analysis affirms the high persistence and adherence observed with diroximel fumarate in patients with multiple sclerosis. Neurol Ther. 2023;12(1):145\u201359.","journal-title":"Neurol Ther"},{"issue":"1","key":"3608_CR9","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1007\/s12325-024-03047-w","volume":"42","author":"Y Mao-Draayer","year":"2025","unstructured":"Mao-Draayer Y, Bar-Or A, Balashov K, et al. Real-world safety and effectiveness of dimethyl fumarate in patients with MS: results from the ESTEEM phase\u00a04 and PROCLAIM phase\u00a03 studies with a focus on older patients. Adv Ther. 2025;42(1):395\u2013412.","journal-title":"Adv Ther"},{"issue":"6","key":"3608_CR10","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1080\/17582024.2025.2564589","volume":"15","author":"C Roman","year":"2025","unstructured":"Roman C, Garabedian M, Schobel VR, et al. Patient and healthcare provider experience of diroximel fumarate: considerations for selecting disease-modifying therapy. Neurodegener Dis Manag. 2025;15(6):271\u201381.","journal-title":"Neurodegener Dis Manag"},{"key":"3608_CR11","unstructured":"Biogen Internal Data. 2025."},{"issue":"5","key":"3608_CR12","doi-asserted-by":"publisher","first-page":"2188","DOI":"10.1172\/JCI72151","volume":"124","author":"H Chen","year":"2014","unstructured":"Chen H, Assmann JC, Krenz A, et al. Hydroxycarboxylic acid receptor\u00a02 mediates dimethyl fumarate\u2019s protective effect in EAE. J Clin Investig. 2014;124(5):2188\u201392.","journal-title":"J Clin Investig"},{"issue":"2","key":"3608_CR13","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1007\/s00401-015-1422-3","volume":"130","author":"B Parodi","year":"2015","unstructured":"Parodi B, Rossi S, Morando S, et al. Fumarates modulate microglia activation through a novel HCAR2 signaling pathway and rescue synaptic dysregulation in inflamed CNS. Acta Neuropathol. 2015;130(2):279\u201395.","journal-title":"Acta Neuropathol"},{"issue":"17","key":"3608_CR14","doi-asserted-by":"publisher","first-page":"4777","DOI":"10.1073\/pnas.1603907113","volume":"113","author":"U Schulze-Topphoff","year":"2016","unstructured":"Schulze-Topphoff U, Varrin-Doyer M, Pekarek K, et al. Dimethyl fumarate treatment induces adaptive and innate immune modulation independent of Nrf2. Proc Natl Acad Sci. 2016;113(17):4777\u201382.","journal-title":"Proc Natl Acad Sci"},{"issue":"6","key":"3608_CR15","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1177\/1352458520937282","volume":"27","author":"EE Longbrake","year":"2021","unstructured":"Longbrake EE, Mao-Draayer Y, Cascione M, et al. Dimethyl fumarate treatment shifts the immune environment toward an anti-inflammatory cell profile while maintaining protective humoral immunity. Mult Scler J. 2021;27(6):883\u201394.","journal-title":"Mult Scler J"},{"issue":"13","key":"3608_CR16","doi-asserted-by":"publisher","first-page":"1729","DOI":"10.1177\/1352458519881761","volume":"26","author":"RT Naismith","year":"2020","unstructured":"Naismith RT, Wolinsky JS, Wundes A, et al. Diroximel fumarate (DRF) in patients with relapsing\u2013remitting multiple sclerosis: interim safety and efficacy results from the phase\u00a03 EVOLVE-MS-1 study. Mult Scler J. 2020;26(13):1729\u201339.","journal-title":"Mult Scler J"},{"issue":"2","key":"3608_CR17","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1007\/s40263-020-00700-0","volume":"34","author":"RT Naismith","year":"2020","unstructured":"The EVOLVE-MS-2 Study Group, Naismith RT, Wundes A, et al. Diroximel fumarate demonstrates an improved gastrointestinal tolerability profile compared with dimethyl fumarate in patients with relapsing\u2013remitting multiple sclerosis: results from the randomized, double-blind, phase\u00a0III EVOLVE-MS-2 study. CNS Drugs. 2020;34(2):185\u201396.","journal-title":"CNS Drugs"},{"issue":"11","key":"3608_CR18","doi-asserted-by":"publisher","first-page":"3154","DOI":"10.1007\/s12325-019-01085-3","volume":"36","author":"MJ Palte","year":"2019","unstructured":"Palte MJ, Wehr A, Tawa M, et al. Improving the gastrointestinal tolerability of fumaric acid esters: early findings on gastrointestinal events with diroximel fumarate in patients with relapsing-remitting multiple sclerosis from the phase\u00a03, open-label EVOLVE-MS-1 Study. Adv Ther. 2019;36(11):3154\u201365.","journal-title":"Adv Ther"},{"issue":"2","key":"3608_CR19","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1007\/s40120-020-00192-6","volume":"9","author":"A Chinea","year":"2020","unstructured":"Chinea A, Amezcua L, Vargas W, et al. Real-world safety and effectiveness of dimethyl fumarate in Hispanic or Latino patients with multiple sclerosis: 3-year results from ESTEEM. Neurol Ther. 2020;9(2):495\u2013504.","journal-title":"Neurol Ther"},{"issue":"12","key":"3608_CR20","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1056\/NEJMoa1206328","volume":"367","author":"RJ Fox","year":"2012","unstructured":"Fox RJ, Miller DH, Phillips JT, et al. Placebo-controlled phase\u00a03 study of oral BG-12 or glatiramer in multiple sclerosis. N Engl J Med. 2012;367(12):1087\u201397.","journal-title":"N Engl J Med"},{"key":"3608_CR21","doi-asserted-by":"publisher","first-page":"175628642091500","DOI":"10.1177\/1756286420915005","volume":"13","author":"R Gold","year":"2020","unstructured":"Gold R, Arnold DL, Bar-Or A, et al. Safety and efficacy of delayed-release dimethyl fumarate in patients with relapsing-remitting multiple sclerosis: 9\u00a0years\u2019 follow-up of DEFINE, CONFIRM, and ENDORSE. Ther Adv Neurol Disord. 2020;13:1756286420915005.","journal-title":"Ther Adv Neurol Disord"},{"issue":"2","key":"3608_CR22","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1007\/s40120-020-00193-5","volume":"9","author":"MJ Williams","year":"2020","unstructured":"Williams MJ, Amezcua L, Okai A, et al. Real-world safety and effectiveness of dimethyl fumarate in Black or African American patients with multiple sclerosis: 3-year results from ESTEEM. Neurol Ther. 2020;9(2):483\u201393.","journal-title":"Neurol Ther"},{"issue":"8","key":"3608_CR23","doi-asserted-by":"publisher","first-page":"1850","DOI":"10.1007\/s00415-018-8916-6","volume":"265","author":"G Mallucci","year":"2018","unstructured":"Mallucci G, Annovazzi P, Miante S, et al. Two-year real-life efficacy, tolerability and safety of dimethyl fumarate in an Italian multicentre study. J Neurol. 2018;265(8):1850\u20139.","journal-title":"J Neurol"},{"key":"3608_CR24","doi-asserted-by":"publisher","first-page":"105094","DOI":"10.1016\/j.msard.2023.105094","volume":"80","author":"LMB Belotti","year":"2023","unstructured":"Belotti LMB, Di Martino M, Zenesini C, et al. Impact of adherence to disease-modifying drugs in multiple sclerosis: a study on Italian real-world data. Mult Scler Relat Disord. 2023;80:105094.","journal-title":"Mult Scler Relat Disord"},{"issue":"9","key":"3608_CR25","first-page":"251","volume":"28","author":"J Burks","year":"2017","unstructured":"Burks J, Marshall TS, Ye X. Adherence to disease-modifying therapies and its impact on relapse, health resource utilization, and costs among patients with multiple sclerosis. Clin Outcomes Res CEOR. 2017;28(9):251\u201360.","journal-title":"Clin Outcomes Res CEOR"},{"key":"3608_CR26","unstructured":"Bureau UC. Census.gov. Health Insurance in the United States: 2024\u2014Tables. https:\/\/www.census.gov\/data\/tables\/2025\/demo\/health-insurance\/p60-288.html. Accessed 23 Jan 2026."},{"key":"3608_CR27","doi-asserted-by":"crossref","unstructured":"Ben-Zacharia AB, Feng JJ, Moss BP, et al. Clinical characteristics and treatment outcomes in multiple sclerosis patients treated with anti-CD20s who switched to fumarates: a retrospective analysis of a US healthcare claims database. J Comp Eff Res. 2025;14(3):e240071.","DOI":"10.57264\/cer-2024-0071"},{"issue":"6","key":"3608_CR28","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1093\/aje\/kwq433","volume":"173","author":"H Quan","year":"2011","unstructured":"Quan H, Li B, Couris CM, et al. Updating and validating the Charlson comorbidity index and score for risk adjustment in hospital discharge abstracts using data from 6 countries. Am J Epidemiol. 2011;173(6):676\u201382.","journal-title":"Am J Epidemiol"},{"issue":"7","key":"3608_CR29","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1212\/01.WNL.0000156155.19270.F8","volume":"64","author":"RHSR Roxburgh","year":"2005","unstructured":"Roxburgh RHSR, Seaman SR, Masterman T, et al. Multiple Sclerosis Severity Score: using disability and disease duration to rate disease severity. Neurology. 2005;64(7):1144\u201351.","journal-title":"Neurology"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-026-03608-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-026-03608-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-026-03608-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T09:19:56Z","timestamp":1782206396000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-026-03608-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,30]]},"references-count":29,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["3608"],"URL":"https:\/\/doi.org\/10.1007\/s12325-026-03608-1","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,30]]},"assertion":[{"value":"13 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"James B. Lewin, Jason P. Mendoza, Babak Amerian-Williams, and Nicholas Belviso are employees of Biogen and may hold stock in the company. Daniel Bandari: consultant for Biogen, EMD Serono; speaker bureaus for Biogen and EMD Serono; research support from EMD Serono (ended) and Genentech. Mirla Avila: consulting fees from Biogen, Genentech, Novartis, and TG Therapeutics (all ended); research support from Biogen (ongoing) and Novartis (ended). Devon Conway: consultant for Alexion, Amgen, Biogen, Bristol Myers Squibb, and Genentech; speaker bureau for Biogen; research support from Biogen and Novartis. Liang Dong, Nicholas Hong, Minxing Li, Anne Littlewood, Mike Roy, Sam Ulin, and Chencan Zou are employees of ClearView Healthcare Partners. ClearView Healthcare Partners was hired by and received compensation from Biogen for the data analysis and writing support associated with this manuscript. They were not compensated for authorship.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"A license was obtained from Forian to access and use the Forian claims database. All patient information was anonymized, and patient confidentiality was maintained through compliance with Health Insurance Portability and Accountability Act regulations. This analysis is based on previously collected data and does not involve any new studies of human or animal subjects.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}